Infectious complications in leukemic patients.
D000208:Acute Disease; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000917:Antibody Formation; D001424:Bacterial Infections / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D003015:Clostridium Infections / Q000175:diagnosis / Q000209:etiology; D003354:Corynebacterium Infections / Q000209:etiology; D003561:Cytarabine / Q000627:therapeutic use; D004357:Drug Synergism; D006506:Hepatitis A / Q000175:diagnosis / Q000209:etiology; D006509:Hepatitis B / Q000175:diagnosis / Q000209:etiology; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D007111:Immunity, Cellular; D007877:Legionnaires' Disease / Q000175:diagnosis / Q000209:etiology; D007938:Leukemia / Q000150:complications* / Q000276:immunology; D008712:Methicillin / Q000627:therapeutic use; D009181:Mycoses / Q000175:diagnosis / Q000209:etiology; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003561:Cytarabine; D008712:Methicillin